Review



bcat inhibitor, ly3351337  (Eli Lilly)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Eli Lilly bcat inhibitor, ly3351337
    a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of <t>LY3351337</t> to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.
    Bcat Inhibitor, Ly3351337, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcat inhibitor, ly3351337/product/Eli Lilly
    Average 90 stars, based on 1 article reviews
    bcat inhibitor, ly3351337 - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart"

    Article Title: Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart

    Journal: Nature Communications

    doi: 10.1038/s41467-021-21962-2

    a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of LY3351337 to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.
    Figure Legend Snippet: a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of LY3351337 to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.

    Techniques Used: Activity Assay, Labeling, Isolation

    Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p.; n = 5; blue), or Veh (DMSO; n = 5; gray), Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min. Fractional percent labeling with 13 C of ( a ) plasma KIV and ( b ) plasma valine. N = 5–6 per group. A separate cohort of Wistar rats was treated with LY3351337 (10 mg/kg i.p.) or vehicle and received an i.p. injection of [U- 13 C]KIV (100 mg/kg) 30 min later. Tissues were harvested 30 min after the [U- 13 C]KIV injection. c Fractional percent labeling with 13 C of valine in plasma and the indicated tissues in the absence (Veh; n = 8) or presence of LY3351337 ( n = 10). The dashed line indicates the plasma enrichment level. Data represent mean ± SEM. Statistical differences indicated by a two-way paired Student’s t -test: * P < 0.05, ** P < 0.005.
    Figure Legend Snippet: Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p.; n = 5; blue), or Veh (DMSO; n = 5; gray), Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min. Fractional percent labeling with 13 C of ( a ) plasma KIV and ( b ) plasma valine. N = 5–6 per group. A separate cohort of Wistar rats was treated with LY3351337 (10 mg/kg i.p.) or vehicle and received an i.p. injection of [U- 13 C]KIV (100 mg/kg) 30 min later. Tissues were harvested 30 min after the [U- 13 C]KIV injection. c Fractional percent labeling with 13 C of valine in plasma and the indicated tissues in the absence (Veh; n = 8) or presence of LY3351337 ( n = 10). The dashed line indicates the plasma enrichment level. Data represent mean ± SEM. Statistical differences indicated by a two-way paired Student’s t -test: * P < 0.05, ** P < 0.005.

    Techniques Used: Injection, Sampling, Labeling, Clinical Proteomics



    Similar Products

    bcat inhibitor, ly3351337  (Eli Lilly)
    90
    Eli Lilly bcat inhibitor, ly3351337
    a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of <t>LY3351337</t> to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.
    Bcat Inhibitor, Ly3351337, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcat inhibitor, ly3351337/product/Eli Lilly
    Average 90 stars, based on 1 article reviews
    bcat inhibitor, ly3351337 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of LY3351337 to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.

    Journal: Nature Communications

    Article Title: Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart

    doi: 10.1038/s41467-021-21962-2

    Figure Lengend Snippet: a Simplified schematic figure diagraming the potential metabolic fates of [U- 13 C]KIV, as well as the effects of LY3351337 to inhibit BCAT activity, and BT2 to inhibit BDK. Label incorporation from first (red circles) and second (blue circles) passes through the TCA cycle are shown in dashed boxes. Measured metabolites in the TCA cycle are highlighted with a gray background and black dashed border. b The fractional percent labeling with 13 C is shown for the indicated metabolites; ( c ) The absolute amounts of 13 C-labeled valine, 3-HIB, citrate, and succinate are shown. Data in b–d are from hearts isolated from Wistar rats and perfused with [U- 13 C]KIV (100 μM) in the absence (Veh; n = 5; gray) or presence of the BDK inhibitor, BT2 ( n = 4; red) or the BCAT inhibitor, LY3351337 ( n = 6; blue). d Rate of reamination (nmol/min) of [U- 13 C]KIV to valine and rate of formation of 13 C-labeled 3-HIB from [U- 13 C]KIV in isolated hearts following treatment with LY3351337 or BT2. Data represent mean ± SEM. Statistical differences indicated by Tukey’s HSD post-hoc test following one-way ANOVA: * P < 0.05, ** P < 0.005, *** P < 0.0005.

    Article Snippet: Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p., Eli Lilly Co.), or vehicle (DMSO, Sigma), male Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg, Cambridge Isotopes), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min.

    Techniques: Activity Assay, Labeling, Isolation

    Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p.; n = 5; blue), or Veh (DMSO; n = 5; gray), Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min. Fractional percent labeling with 13 C of ( a ) plasma KIV and ( b ) plasma valine. N = 5–6 per group. A separate cohort of Wistar rats was treated with LY3351337 (10 mg/kg i.p.) or vehicle and received an i.p. injection of [U- 13 C]KIV (100 mg/kg) 30 min later. Tissues were harvested 30 min after the [U- 13 C]KIV injection. c Fractional percent labeling with 13 C of valine in plasma and the indicated tissues in the absence (Veh; n = 8) or presence of LY3351337 ( n = 10). The dashed line indicates the plasma enrichment level. Data represent mean ± SEM. Statistical differences indicated by a two-way paired Student’s t -test: * P < 0.05, ** P < 0.005.

    Journal: Nature Communications

    Article Title: Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart

    doi: 10.1038/s41467-021-21962-2

    Figure Lengend Snippet: Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p.; n = 5; blue), or Veh (DMSO; n = 5; gray), Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min. Fractional percent labeling with 13 C of ( a ) plasma KIV and ( b ) plasma valine. N = 5–6 per group. A separate cohort of Wistar rats was treated with LY3351337 (10 mg/kg i.p.) or vehicle and received an i.p. injection of [U- 13 C]KIV (100 mg/kg) 30 min later. Tissues were harvested 30 min after the [U- 13 C]KIV injection. c Fractional percent labeling with 13 C of valine in plasma and the indicated tissues in the absence (Veh; n = 8) or presence of LY3351337 ( n = 10). The dashed line indicates the plasma enrichment level. Data represent mean ± SEM. Statistical differences indicated by a two-way paired Student’s t -test: * P < 0.05, ** P < 0.005.

    Article Snippet: Thirty minutes after a single injection of BCAT inhibitor, LY3351337 (10 mg/kg i.p., Eli Lilly Co.), or vehicle (DMSO, Sigma), male Wistar rats received an i.p. injection of [U- 13 C]KIV (100 mg/kg, Cambridge Isotopes), followed by blood sampling from the tail vein at 2, 5, 10, 15, 30, and 60 min.

    Techniques: Injection, Sampling, Labeling, Clinical Proteomics